CA2217227C - Use of a partial or complete extract of not fermented camellia sinensis l. for the preparation of a medicament, a medical care product, a cosmetic preparation or a food complementary product - Google Patents
Use of a partial or complete extract of not fermented camellia sinensis l. for the preparation of a medicament, a medical care product, a cosmetic preparation or a food complementary product Download PDFInfo
- Publication number
- CA2217227C CA2217227C CA002217227A CA2217227A CA2217227C CA 2217227 C CA2217227 C CA 2217227C CA 002217227 A CA002217227 A CA 002217227A CA 2217227 A CA2217227 A CA 2217227A CA 2217227 C CA2217227 C CA 2217227C
- Authority
- CA
- Canada
- Prior art keywords
- use according
- cells
- cell
- preparation
- caused
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is directed to the use of a partial or complete extract of not fermented Camellia sinensis L. for the preparation of a medicament, a medical care product, a cosmetic preparation or a food complementary product, whereby these preparations - prevent or at least reduce considerably the formation of necrosis and/or atrophies in human or animal tissues and/or the premature mortification of vascularized and non-vascularized cells and cellular tissues/colonies in the human or animal body, and - not only promote the adhesion between single, to the same tissue type belonging cells or cell unions, - but also prevent or at least reduce considerably the adhesion between single, to different not histo-compatible tissue types belonging cells or cell unions.
Description
., 1 Use of a partial or complete extract of not fermented Camellia sinensis L. for the preparation of a medica-ment, a medical care product, a cosmetic preparation or a food complementary product The present invention is directed to the use of a partial or complete extract of not fermented Camel-lia sinensis L. for the preparation of a medicament, a medical care product, a cosmetic preparation or a food complementary product.
Preparations of Camellia sinensis L. for medi-cal and cosmetic applications are known; see "Hagers Handbuch der Pharmazeutischen Praxis", Vol. 4, Drogen A-D, Springer-Verlag, (1992), pages 628 - 640.
Due to its content compounds Camellia sinensis L. has a central stimulating, moderate diuretic, in de-pendence of the extraction time more or less strong con-stipatory/anti-diarrhoeal, the heart activity promoting and possibly antiarteriosclerotic effect, see Stagg G.V., Millin D.J., (1975), J. Sci. Food. Agric. 26, pa-ges 1439 - 1459.
The further prior art concerning Camellia si-nensis L. is described in Zeitschrift fur Phytotherapie 17, (1995), pages 231 - 250.
So are especially assigned to the in Camellia sinensis L. contained polyphenols an antioxidant effi-cacy, which shall protect the human body from so called radicals.
The polyphenols are also assigned to have an anti-inflammatory efficacy.
An inhibition of the tumor formation by means of Camellia sinensis L. extracts has been proved in ani-mal experiments and is supported by epidemiological stu-dies.
Also mentioned are virostatic and bacteriosta-tic effects of Camellia sinensis L. extracts.
In JP 07/101 837 is described an agent having anti-dandruff activity. As active component this agent contains an alcoholic extract of not further specified tea leaves.
In JP 06/056 687 is described an agent with which is removed dental tartar, and with which the for-mation of dental tartar is prevented.
As active components this agent contains an aqueous or a with a hydrophilic organic solvent obtained extract of tea leaves (Camellia sinensis).
For the claimed activity has been made respon-sible the strong antimicrobial effect against periodon-totic pathogenic bacterias.
In JP 08/073 350 is described an agent for the improvement of cerebral functions.
As active component is mentioned theanine (glutamic acid ethylamide). This component may be con-tained in tea extracts.
In JP 06/100 442 is described an anti-stress agent for the prevention or mitigatlon of mental and physical diseases due to stress.
As active component this agent contains L-theanine of native origin as such or in the form of a pharmaceutically acceptable salt, for example the hydro-chloride.
5In US 5 071 653 are described processes for the preparation of extracts of Camellia sinensis.
These extracts promote the growth of bifido-bacterias.
These extracts contain in contrary to tea in-fusions, partial and complete extracts of not fermented Camellia sinensis neither flavone glucosides nor poly-phenols, and also no therpenoides and no lipophilic com-pounds.
With these in US 5 071 653 described processes are made highly selective fractionations of Camellia si-nensis content compounds, which have a completely unu-sual activity spectra, that is the promotion of the growth of intestine bacterias.
Quite surprisingly were found new use possibi-lities of partial or complete extracts of not fermentedCamelia sinensis L.
The present invention is directed to the use of a partial or complete extract of not fermented Camel-lia sinensis L. for the preparation of a medicament, a medical care product, a cosmetic preparation or a food complementary product, whereby these preparations - prevent or at least reduce considerably the formation of necrosis and/or atrophies in human or ani-mal tissues and/or the premature mortification of vascu-larized and non-vascularized cells and cellular tissu-es/colonies in the human or animal body, and - not only promote the adhesion between sing-le, to the same tissue type belonging cells or cell uni-ons, - but also prevent or at least reduce consi-derably the adhesion between single, to different not histo-compatible tissue types belonging cells or cell unions.
Preferred embodiments of this invention are defined in the dependent claims.
The extract of Camellia sinensis L. used for the examinations described below was prepared as fol-lows.
6 kg dried, not fermented Camellia sinensis L.
(folia) were extracted under stirring with 60 kg of a mixture of 8 parts by weight of ethanol and 2 parts by weight of water at a temperature from 25~C to 35~C du-ring 2 hours.
Then was filtered, and the solvent mixture was evaporated at a pressure from 50 mbar to 150 mbar and a temperature from 30~C to 40~C up to a complete evapora-tion of ethanol.
From the so obtained concentrate were removed according to EP 0 730 830 A1 the undesired lipophilic contaminations and residues.
The so purified extract was then subjected to a process for a decrease of the bacterial count (30 se-conds at a temperature of 120~C).
Then this extract was spray dried.
There was obtained 1 kg of native dry extract having the following analysis datas.
50 % m/m phenylchroman derivatives, calculated as epicatechin (HPLC), 6 % m/m caffeine (HPLC) 1 % m/m theobromine (HPLC).
In addition were detected qualitatively:
glutaminic acid-ethylamide flavonoides and plant acids (HPTLC).
This product is obtainable from the company Emil Flachsmann AG in CH-8820 Wadenswil / Switzerland under the denotation "EFLA 85942".
This product was tested on its effects on a special cell model, that is the multicellular spheroids.
These spheroids are ball-shaped cell aggrega-tes, which contain in suspension culture at a diameter of about 1 mm up to 100'000 cells, and as a rule reflect better the biological relations of cell unions in vivo than conventional monolayer cultures.
Experiment 1 Tested was the influence of the product "EFLA
85942" onto the volume growth of these spheroids as a function of the cultivation length and at different con-centrations of "EFLA 85942" in comparision to control cultures.
The following results were obtained.
As expected "EFLA 85942" effected a systematic and in large ranges of the growth length a significant reduction of the volume growth of the spheroids.
But quite surprisingly no concentration depen-dence could be detected thereby after the beginning of the effect over a broad concentration range.
This effect points to a high therapeutical width.
In addition it was noted quite surprisingly that the with "EFLA 85942" treated spheroides formed no noteworthy necrosis during the whole growth phase.
In control cultures which were not treated with "EFLA 85942" already at diameters of about 200 micrometers were detected central necrosis which in-creased strongly during the growth phase.
At the end of the duration of test the untrea-ted spheroids showed only a very thin vital border lay-er.
This occurance of necrosis is typical for the used experimental model.
This behaviour of the with "EFLA 85942" trea-ted spheroids has not yet been observed.
It is persumed that the known antioxidative effect of the polyphenols can not be responsible alone for this behaviour.
On behalf of this may be used also the res~lts which were obtained from accompanying investigations on singly cells; see experiment 2.
Experiment 2 In a first experiment were sowed colon car-cinoma cells under the influence of "EFLA 85942" in so called adhered culture flasks.
Expected was the formation of a so called mo-nolayer-film.
But quite surprisingly was observed the forma-tion of three-dimensional, strongly connected cell ag-gregates.
Also this behaviour has not yet been observed.
In addition were observed in the culture media nearly no non-adhered single cells.
In a second experiment some few single cells were sowed in non-adhered Petri dishes, with the aim to analyze the influence of "EFLA 85942" onto the colony generation ability of these single cells.
Thereby two variants were carried out.
In experiment A was added "EFLA 85942" to the cells after an initial adhesion on the Petri dish.
In experiment B was added "EFLA 85942" to the cells immediately before the adhesion process.
In these two experiments could be determined a statistical significant decrease of the colony generati-on ability which occured in experiment B, in comparision to experiment A, in a drastic stronger extent.
The result of these two experiments, together with the above described formation of three-dimensional cell aggregates, allows the conclusion that on one hand the adhesion with non histo-compatible structures is re-duced and that on the other hand the adhesion betweeen single, to the same tissue type belonging cells or cell unions is promoted.
These behaviour characteristics prove that be-side the above mentioned antioxidative effect of the po-lyphenols still further effect mechanisms and/or further active compounds play an important rule.
The treatment of the human or animal body may consist therein that the corresponding preparation is taken or is applied internal or external.
The treatment is carried out at least during such a long time until the corresponding symptomatic has disappeared.
The following examples illustrate the present S invention.
Example 1 Preparing of a preparation in the form of a hard gelatin capsule.
For the preparation of 1000 capsules of the size "one " 100 g of "EFLA 85942" were mixed homogene-ously with 25 g of microcristalline cellulose, 4 g of magnesium stearate and 1 g of precipitated silicic acid.
This mixture was filled in a respective amount of 150 mg into hard gelatin capsules.
Example 2 Preparing of a preparation in the form of a drinking ampule.
For the preparation of 1000 drinking ampuls of 10 ml 100 g of "EFLA 85942" were mixed homogeneously with 15 g of potassium sorbate, 15 g of sodium benzoate, 500 g of fructose and 10 g of sodium chloride.
This mixture was filled up with a solution of 95 parts by weight of water and 5 parts by weight of glycerol to a total volume of 10 liters, mixed and fil-tered sterile.
The obtained filtrate was filled aseptic into the drinking ampules.
Example 3 Preparing of a preparation in the form of a liposome gel.
Phase A
- 1.0 parts by weight of RhodigelR 200, - 8.0 parts by weight of 1,2-propylene glycol were mixed at room temperature and were allo-wed to swell during one hour.
Phase B
- 6.5 parts by weight Phospholipon 80, - 10.0 parts by weight of polyethylene glycol 400, - 2.0 parts by weight of glycerol were mixed together at a temperature from 60~C
to 70~C and were homogenized.
The obtained homogeneous mixture was cooled to a temperature from 38~C to 40~C under stirring.
Phase C
A mixture of - 71.7 parts by weight of distilled water, - 1.2 parts by weight of "EFLA 85942"
was filtered sterile and was then incorporated drop by drop into the phase B. After the complete addi-tion the obtained mixture was cooled to room tempera-ture, incorporated in portions into the phase A and ho-mogenlzed.
The obtained preparation can be filled in pla-stic squezze bottles of 10 ml.
The preparation was prepared unter aseptic conditions.
Application example 1 A 30 years old female healthy test person with head hair problems in the form of thin areas and par-tially growed places took over a time of 8 weeks daily 3capsules according to example 1.
Within this time the state of the head hair changed drastically.
In the growed hair areas germinated normally coloured hairs, and the thin areas disappeared.
Application example 2 A 36 years old male healthy test person with head hair problems in the form of thin areas and par-tially growed places took over a time of 8 weeks daily 6 capsules according to example 1.
Within this time the state of the head hair changed drastically.
In the growed hair areas germinated normally coloured hairs, and the thin areas disappeared.
Preparations of Camellia sinensis L. for medi-cal and cosmetic applications are known; see "Hagers Handbuch der Pharmazeutischen Praxis", Vol. 4, Drogen A-D, Springer-Verlag, (1992), pages 628 - 640.
Due to its content compounds Camellia sinensis L. has a central stimulating, moderate diuretic, in de-pendence of the extraction time more or less strong con-stipatory/anti-diarrhoeal, the heart activity promoting and possibly antiarteriosclerotic effect, see Stagg G.V., Millin D.J., (1975), J. Sci. Food. Agric. 26, pa-ges 1439 - 1459.
The further prior art concerning Camellia si-nensis L. is described in Zeitschrift fur Phytotherapie 17, (1995), pages 231 - 250.
So are especially assigned to the in Camellia sinensis L. contained polyphenols an antioxidant effi-cacy, which shall protect the human body from so called radicals.
The polyphenols are also assigned to have an anti-inflammatory efficacy.
An inhibition of the tumor formation by means of Camellia sinensis L. extracts has been proved in ani-mal experiments and is supported by epidemiological stu-dies.
Also mentioned are virostatic and bacteriosta-tic effects of Camellia sinensis L. extracts.
In JP 07/101 837 is described an agent having anti-dandruff activity. As active component this agent contains an alcoholic extract of not further specified tea leaves.
In JP 06/056 687 is described an agent with which is removed dental tartar, and with which the for-mation of dental tartar is prevented.
As active components this agent contains an aqueous or a with a hydrophilic organic solvent obtained extract of tea leaves (Camellia sinensis).
For the claimed activity has been made respon-sible the strong antimicrobial effect against periodon-totic pathogenic bacterias.
In JP 08/073 350 is described an agent for the improvement of cerebral functions.
As active component is mentioned theanine (glutamic acid ethylamide). This component may be con-tained in tea extracts.
In JP 06/100 442 is described an anti-stress agent for the prevention or mitigatlon of mental and physical diseases due to stress.
As active component this agent contains L-theanine of native origin as such or in the form of a pharmaceutically acceptable salt, for example the hydro-chloride.
5In US 5 071 653 are described processes for the preparation of extracts of Camellia sinensis.
These extracts promote the growth of bifido-bacterias.
These extracts contain in contrary to tea in-fusions, partial and complete extracts of not fermented Camellia sinensis neither flavone glucosides nor poly-phenols, and also no therpenoides and no lipophilic com-pounds.
With these in US 5 071 653 described processes are made highly selective fractionations of Camellia si-nensis content compounds, which have a completely unu-sual activity spectra, that is the promotion of the growth of intestine bacterias.
Quite surprisingly were found new use possibi-lities of partial or complete extracts of not fermentedCamelia sinensis L.
The present invention is directed to the use of a partial or complete extract of not fermented Camel-lia sinensis L. for the preparation of a medicament, a medical care product, a cosmetic preparation or a food complementary product, whereby these preparations - prevent or at least reduce considerably the formation of necrosis and/or atrophies in human or ani-mal tissues and/or the premature mortification of vascu-larized and non-vascularized cells and cellular tissu-es/colonies in the human or animal body, and - not only promote the adhesion between sing-le, to the same tissue type belonging cells or cell uni-ons, - but also prevent or at least reduce consi-derably the adhesion between single, to different not histo-compatible tissue types belonging cells or cell unions.
Preferred embodiments of this invention are defined in the dependent claims.
The extract of Camellia sinensis L. used for the examinations described below was prepared as fol-lows.
6 kg dried, not fermented Camellia sinensis L.
(folia) were extracted under stirring with 60 kg of a mixture of 8 parts by weight of ethanol and 2 parts by weight of water at a temperature from 25~C to 35~C du-ring 2 hours.
Then was filtered, and the solvent mixture was evaporated at a pressure from 50 mbar to 150 mbar and a temperature from 30~C to 40~C up to a complete evapora-tion of ethanol.
From the so obtained concentrate were removed according to EP 0 730 830 A1 the undesired lipophilic contaminations and residues.
The so purified extract was then subjected to a process for a decrease of the bacterial count (30 se-conds at a temperature of 120~C).
Then this extract was spray dried.
There was obtained 1 kg of native dry extract having the following analysis datas.
50 % m/m phenylchroman derivatives, calculated as epicatechin (HPLC), 6 % m/m caffeine (HPLC) 1 % m/m theobromine (HPLC).
In addition were detected qualitatively:
glutaminic acid-ethylamide flavonoides and plant acids (HPTLC).
This product is obtainable from the company Emil Flachsmann AG in CH-8820 Wadenswil / Switzerland under the denotation "EFLA 85942".
This product was tested on its effects on a special cell model, that is the multicellular spheroids.
These spheroids are ball-shaped cell aggrega-tes, which contain in suspension culture at a diameter of about 1 mm up to 100'000 cells, and as a rule reflect better the biological relations of cell unions in vivo than conventional monolayer cultures.
Experiment 1 Tested was the influence of the product "EFLA
85942" onto the volume growth of these spheroids as a function of the cultivation length and at different con-centrations of "EFLA 85942" in comparision to control cultures.
The following results were obtained.
As expected "EFLA 85942" effected a systematic and in large ranges of the growth length a significant reduction of the volume growth of the spheroids.
But quite surprisingly no concentration depen-dence could be detected thereby after the beginning of the effect over a broad concentration range.
This effect points to a high therapeutical width.
In addition it was noted quite surprisingly that the with "EFLA 85942" treated spheroides formed no noteworthy necrosis during the whole growth phase.
In control cultures which were not treated with "EFLA 85942" already at diameters of about 200 micrometers were detected central necrosis which in-creased strongly during the growth phase.
At the end of the duration of test the untrea-ted spheroids showed only a very thin vital border lay-er.
This occurance of necrosis is typical for the used experimental model.
This behaviour of the with "EFLA 85942" trea-ted spheroids has not yet been observed.
It is persumed that the known antioxidative effect of the polyphenols can not be responsible alone for this behaviour.
On behalf of this may be used also the res~lts which were obtained from accompanying investigations on singly cells; see experiment 2.
Experiment 2 In a first experiment were sowed colon car-cinoma cells under the influence of "EFLA 85942" in so called adhered culture flasks.
Expected was the formation of a so called mo-nolayer-film.
But quite surprisingly was observed the forma-tion of three-dimensional, strongly connected cell ag-gregates.
Also this behaviour has not yet been observed.
In addition were observed in the culture media nearly no non-adhered single cells.
In a second experiment some few single cells were sowed in non-adhered Petri dishes, with the aim to analyze the influence of "EFLA 85942" onto the colony generation ability of these single cells.
Thereby two variants were carried out.
In experiment A was added "EFLA 85942" to the cells after an initial adhesion on the Petri dish.
In experiment B was added "EFLA 85942" to the cells immediately before the adhesion process.
In these two experiments could be determined a statistical significant decrease of the colony generati-on ability which occured in experiment B, in comparision to experiment A, in a drastic stronger extent.
The result of these two experiments, together with the above described formation of three-dimensional cell aggregates, allows the conclusion that on one hand the adhesion with non histo-compatible structures is re-duced and that on the other hand the adhesion betweeen single, to the same tissue type belonging cells or cell unions is promoted.
These behaviour characteristics prove that be-side the above mentioned antioxidative effect of the po-lyphenols still further effect mechanisms and/or further active compounds play an important rule.
The treatment of the human or animal body may consist therein that the corresponding preparation is taken or is applied internal or external.
The treatment is carried out at least during such a long time until the corresponding symptomatic has disappeared.
The following examples illustrate the present S invention.
Example 1 Preparing of a preparation in the form of a hard gelatin capsule.
For the preparation of 1000 capsules of the size "one " 100 g of "EFLA 85942" were mixed homogene-ously with 25 g of microcristalline cellulose, 4 g of magnesium stearate and 1 g of precipitated silicic acid.
This mixture was filled in a respective amount of 150 mg into hard gelatin capsules.
Example 2 Preparing of a preparation in the form of a drinking ampule.
For the preparation of 1000 drinking ampuls of 10 ml 100 g of "EFLA 85942" were mixed homogeneously with 15 g of potassium sorbate, 15 g of sodium benzoate, 500 g of fructose and 10 g of sodium chloride.
This mixture was filled up with a solution of 95 parts by weight of water and 5 parts by weight of glycerol to a total volume of 10 liters, mixed and fil-tered sterile.
The obtained filtrate was filled aseptic into the drinking ampules.
Example 3 Preparing of a preparation in the form of a liposome gel.
Phase A
- 1.0 parts by weight of RhodigelR 200, - 8.0 parts by weight of 1,2-propylene glycol were mixed at room temperature and were allo-wed to swell during one hour.
Phase B
- 6.5 parts by weight Phospholipon 80, - 10.0 parts by weight of polyethylene glycol 400, - 2.0 parts by weight of glycerol were mixed together at a temperature from 60~C
to 70~C and were homogenized.
The obtained homogeneous mixture was cooled to a temperature from 38~C to 40~C under stirring.
Phase C
A mixture of - 71.7 parts by weight of distilled water, - 1.2 parts by weight of "EFLA 85942"
was filtered sterile and was then incorporated drop by drop into the phase B. After the complete addi-tion the obtained mixture was cooled to room tempera-ture, incorporated in portions into the phase A and ho-mogenlzed.
The obtained preparation can be filled in pla-stic squezze bottles of 10 ml.
The preparation was prepared unter aseptic conditions.
Application example 1 A 30 years old female healthy test person with head hair problems in the form of thin areas and par-tially growed places took over a time of 8 weeks daily 3capsules according to example 1.
Within this time the state of the head hair changed drastically.
In the growed hair areas germinated normally coloured hairs, and the thin areas disappeared.
Application example 2 A 36 years old male healthy test person with head hair problems in the form of thin areas and par-tially growed places took over a time of 8 weeks daily 6 capsules according to example 1.
Within this time the state of the head hair changed drastically.
In the growed hair areas germinated normally coloured hairs, and the thin areas disappeared.
Claims (21)
1. Use of a partial or complete extract of un-fermented Camellia sinensis L. for the preparation of a medicament, a medical care product, a cosmetic prepara-tion or a food complementary product, whereby these pre-parations - prevent or at least reduce considerably the formation of necrosis and/or atrophies in human or ani-mal tissues and/or the premature mortification of vascu-larized and non-vascularized cells and cellular tissu-es/colonies in the human or animal body, and - not only promote the adhesion between sing-le, to the same tissue type belonging cells or cell uni-ons, - but also prevent or at least reduce consi-derably the adhesion between single, to different not histo-compatible tissue types belonging cells or cell unions.
2. Use according to claim 1, characterized in that the medicament or the medical care product is in a pharmaceutically acceptable administrative form.
3. Use according to claim 2, characterized in that the pharmaceutical acceptable administrative form is a - solid administrative form for oral applica-tion, - liquid administrative form for oral, paren-teral, rectal, vaginal and tropic application, - semisolid administrative form for topic, oral, rectal and vaginal application.
4. Use according to claim 3, characterized in that the solid administrative form is a tablet, a film-tablet, a dragee, a pellet, a hard gelatin-capsule or a soft gelatin-capsule.
5. Use according to claim 3, characterized in that the liquid administrative form is a dropping solu-tion, a spray, an injection solution or a syrup.
6. Use according to claim 3, characterized in that the semisolid administrative form is a cream, a gel, an ointment, a paste or a suppository.
7. Use according to claim 1, characterized in that the cosmetic preparation or the food complementary product is in the form of a solution, a spray, a cream, a gel, an ointment, a paste, a dragee, a capsule, an am-pule or a shampoo.
8. Use according to any one of claims 1 to 7, cha-racterized in that the partial or complete extract is incorporated into nano-capsules or into liposomes.
9 . Use according to any one of clam 1 to 8, cha-racterized in that said preparations contain additional-ly at least one additive and/or auxiliary agent.
10. Use according to claim 9, characterized in that, the additive and/or auxiliary agent is selected from the group, consisting of emulsifiers, stabilizers, antioxidants, dyestuffs, aromas, disintegration agents, solvents, lubricants and surfactants.
11. Use according to any one of claims 1 to 10, characterized in that the partial or complete extract is contained in an amount from 0.1 % by weight to 95 % by weight, referred to the total weight of the preparation.
12. Use according to any one of claims 1 to 11, characterized in that the partial or complete extract contains besides native polyphenols and purine alkaloids additionally at least one further native compound, se-lected from the group consisting of glutamic acid ethyl-amide, glutamic acid, including their physiologically salts, and glutamine.
13. Use according to any one of claims 1 to 12, characterized in that said preparations serve for the prevention, treatment or post-treatment of - cachectic states, caused by small intestine villus atrophies, - malabsorptions, caused by small intestine villus atrophies, - polyneuropathias, caused by non-inflammatory axon damages, - parodontosis, caused by gingiva cell growth disorders and cell-cell-adhesion disorders, - loss of hair, caused by hair root atrophies, - hypertrophic skin changes, - hyperplasias, caused by pathological cell propagation, - leukozytes-maturation disorders, - exsudative forms of the tuberculosis of the lungs, - zirrhosis of the lungs, - zirrhosis of the liver, - emphysemas of the lungs, or - erythematodes visceralis.
14. Use according to claim 13, characterized in that the hypertrophic skin changes are psoriasis vul-garis, neurodermitis, caused by cell-cell-adhesion di-sorders and lacks of differentiation.
15. Use according to claim 13, characterized in that the hyperplasias are hypersplenism, caused by lymphogranulomatosis, foveolic hyperplasia of the ga-stric mucosa.
16. Use according to claim 13, characterized in that the leukozytes-maturation disorders are leukae-mias of the subspecies a.) acute lymphatic leukaemia, b.) chronic lymphatic leukaemia,
17 c.) acute myeloic leukaemia, or d.) chronic myeloic leukaemia.
17. Use according to claim 16, characterized in that the acute myeloic leukaemia is of the peroxida-se-type.
17. Use according to claim 16, characterized in that the acute myeloic leukaemia is of the peroxida-se-type.
18. Use according to claim 13, characterized in that the zirrhosis of the lungs is chronic intersti-tial fibrosis with parenchyma depletion.
19. Use according to claim 13, characterized in that the zirrhosis of the liver is a consequence of chronic hepatitis.
20. Use according to any one of claims 1 to 19, characterized in that said preparations serve for the treatment of human or animal cell and/or tissue cultures as well as organs outside the human or animal body.
21. Use according to claim 20, characterized in that said preparations serve for the cultivation and propagation and/or the three-dimensional reconstruction of cartilage cells, gingiva cells, hair root cells, skin cells and skin tissues, retina cells and retina tissues, heart muscle cells and heart muscle tissues, liver cells and liver tissues.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH02606/96A CH690816A5 (en) | 1996-10-24 | 1996-10-24 | Using a partial or Vollextrates from unfermented Camellia sinensis L. for the manufacture of a medicament, a medical product, a cosmetic product or a dietary supplement product. |
| CH19962606/96 | 1996-10-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2217227A1 CA2217227A1 (en) | 1998-04-24 |
| CA2217227C true CA2217227C (en) | 2001-10-23 |
Family
ID=4237549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002217227A Expired - Fee Related CA2217227C (en) | 1996-10-24 | 1997-10-24 | Use of a partial or complete extract of not fermented camellia sinensis l. for the preparation of a medicament, a medical care product, a cosmetic preparation or a food complementary product |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0845264A1 (en) |
| AU (1) | AU697483B2 (en) |
| CA (1) | CA2217227C (en) |
| CH (1) | CH690816A5 (en) |
| ES (1) | ES2120397T1 (en) |
| ZA (1) | ZA979577B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2320368C (en) | 1998-02-23 | 2007-08-21 | Taiyo Kagaku Co., Ltd. | Composition comprising theanine |
| DE19824727A1 (en) * | 1998-06-03 | 1999-12-09 | Beiersdorf Ag | Cosmetic or dermatological preparations containing catechins or green tea extract |
| JP5230042B2 (en) | 1999-06-02 | 2013-07-10 | 株式会社ビーエムジー | Preservatives for animal cells or organs and methods for their preservation. |
| JP4908718B2 (en) * | 2000-07-05 | 2012-04-04 | 株式会社大塚製薬工場 | Cell / tissue preservation solution |
| AU2003261860A1 (en) * | 2002-08-30 | 2004-03-19 | Masashi Komeda | Composition for protecting organ, tissue or cell and utilization thereof |
| DE10311984A1 (en) * | 2003-03-12 | 2004-09-23 | Freie Universität Berlin | Using neutral endopeptidase-associated molecules for treatment, diagnosis, prophylaxis and monitoring of eating and metabolic disorders and dementia, also for drug development |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5071653A (en) * | 1989-02-09 | 1991-12-10 | Itoen Ltd. | Camellia sinensis extracts that promote the growth of bifidobacterium |
| FR2651132B1 (en) * | 1989-08-30 | 1993-01-08 | Pacific Chem Co Ltd | PROTECTIVE AGENTS FOR CELLS AGAINST CHEMICAL SPECIES WITH ACTIVE OXYGEN AND THEIR PREPARATION. |
| JPH0813738B2 (en) * | 1992-08-04 | 1996-02-14 | 株式会社 伊藤園 | Plaque remover and tartar deposition inhibitor |
| JP2904655B2 (en) * | 1992-09-17 | 1999-06-14 | サントリー株式会社 | Anti-stress agent |
| JP3516306B2 (en) * | 1993-10-05 | 2004-04-05 | 三和生薬株式会社 | New dandruff agent |
| JPH0873350A (en) * | 1994-09-06 | 1996-03-19 | Itouen:Kk | Cerebral function-improving agent, food and beverage |
-
1996
- 1996-10-24 CH CH02606/96A patent/CH690816A5/en not_active IP Right Cessation
-
1997
- 1997-10-24 CA CA002217227A patent/CA2217227C/en not_active Expired - Fee Related
- 1997-10-24 EP EP97118480A patent/EP0845264A1/en not_active Withdrawn
- 1997-10-24 ES ES97118480T patent/ES2120397T1/en active Pending
- 1997-10-24 AU AU42813/97A patent/AU697483B2/en not_active Ceased
- 1997-10-24 ZA ZA9709577A patent/ZA979577B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU4281397A (en) | 1998-06-04 |
| CH690816A5 (en) | 2001-01-31 |
| ES2120397T1 (en) | 1998-11-01 |
| AU697483B2 (en) | 1998-10-08 |
| EP0845264A1 (en) | 1998-06-03 |
| CA2217227A1 (en) | 1998-04-24 |
| ZA979577B (en) | 1998-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0918458B1 (en) | Antimicrobial treatment for herpes simplex virus and other infectious diseases | |
| JP2010518180A (en) | Novel cosmetic and / or pharmaceutical compositions and their uses | |
| US20120328721A1 (en) | Aloe vera sprout concentrate or extract having superior skin cell growth promotion, antioxidant, and anti-allergy effects | |
| EP0680761B1 (en) | Topical medicament having cicatrizing activity | |
| CN110876760A (en) | Skin external composition with wound healing promoting and/or scar repairing effects | |
| CN101410100A (en) | Method and composition for treating acne using lignan compounds | |
| KR20190013575A (en) | composition for preventing of hair loss or promoting hair growth | |
| CA2217227C (en) | Use of a partial or complete extract of not fermented camellia sinensis l. for the preparation of a medicament, a medical care product, a cosmetic preparation or a food complementary product | |
| JP2000191542A (en) | Preventive/therapeutic agent for osteoporosis | |
| TW201817438A (en) | Composition containing extract of yellow-turning/turned leaf of soybean for preventing hair loss or improving hair growth and use thereof | |
| JP3998085B2 (en) | Hyaluronic acid amount increase accelerator | |
| EP2708232B1 (en) | Composition comprising a Centella asiatica plant suspension cell culture | |
| EP0471388B1 (en) | Medicament for the treatment of cardiac insufficiency | |
| KR101273027B1 (en) | Composition for inhibiting sebum secretion and anti-obesity comprising kaempferol | |
| US20150258158A1 (en) | Compositions and methods for inhibition of triglyceride synthesis via synergistic combination of botanical formulations | |
| US20020127286A1 (en) | Method for the treatment of human or animal cells, tissue cultures and/or organs outside the human or animal body | |
| WO2023106879A1 (en) | Composition comprising cassia mimosoides extract as active ingredient for improving hair or scalp condition | |
| CN111991413B (en) | Polysaccharide composition for preventing alopecia or promoting hair growth, and preparation and application thereof | |
| EP1661565B1 (en) | Composition comprising l-proline for the treatment of vitiligo | |
| EP4344556A1 (en) | Composition comprising hydrangenol as active ingredient for improving hair or scalp condition | |
| CN107362184A (en) | The purposes of penthorum chinense pursh and its extract in the oral cavity medicine thing for the treatment of or/and prevention of gingivitis is prepared | |
| KR102599144B1 (en) | Composition comprising an extract of Ganoderma lucidum for improving hair or scalp condition | |
| US7118769B2 (en) | Pharmaceutical compositions containing Bulbophyllum | |
| KR20230087049A (en) | A composition for improving hair or scalp condition comprising a plant extract as an active ingredient | |
| KR20160056620A (en) | Composition for Preventing Biofilm Formation Containing Enzyme Treated Extract of licorice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |